Ocuphire Pharma to Present at Euretina and Retina Society Conferences in October

<p>Presentations Will Feature Data From ZETA-1 Phase 2 Trial of APX3330 in Diabetic Retinopathy FARMINGTON HILLS, Mich., Oct. 06, 2023 (GLOBE NEWSWIRE) — Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing small-molecule therapies for the treatment of retinal and refractive eye disorders, today announced presentations featuring results from […]</p>
<p>The post <a rel="nofollow" href="https://forextv.com/top-news/ocuphire-pharma-to-present-at-euretina-and-retina-society-conferences-in-october/">Ocuphire Pharma to Present at Euretina and Retina Society Conferences in October</a> appeared first on <a rel="nofollow" href="https://forextv.com">ForexTV</a>.</p>